Astellas Venture Management, the corporate venturing division of Japan-based pharmaceutical company Astellas, has participated in a £3.8m ($6m) tranched equity financing for Bicycle Therapeutics, a UK-based biotherapeutics startup spun out of the UK Medical Research Council’s Laboratory of Molecular Biology in 2009. 

Return backers venture capital firm Atlas Venture, Novartis Venture Fund, the $750m corporate venturing unit of pharmaceutical firm Novartis,  SR One, the corporate venturing unit of GlaxoSmithKline, and venture firm SV Life Sciences were also involved.


Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?